Q32 Bio Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Q32 Bio is in Stage 3, the topping phase, now in week 5 (since Sep 22, 2026). It closed at $8.80, 58.8% below its 52-week high and below its 200-day average, which is rising.

$8.80

-1.29% today

$262M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is QTTB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 16w

S4 29w

S2 48w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 6w → S2 2w → S1 1w → S4 17w → S1 8w → S2 11w → S3 5w → S2 16w → S3 5w → S4 29w → S1 10w → S4 2w → S1 1w → S2 48w → S3 4w current

Total tracked: 165 weeks across 15 stage runs.

QTTB among Biotechnology14th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…14	QTTBQ32 Bio Inc.	Stage 3 · wk 5	98	−7.9%

vs 52W High

-58.8%

$1.93 lo$21.38 hi

58.8% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-3.1%

200 DMA: $9.08 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.47x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.9%

-41.9%

+35.8%

YTD

+155.8%

+196.3%

Scan Membership

Breakout Watch

Latest: 2024-07-30

6 appearances in last 60 days. First seen: 2019-01-11.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.47x

2026-10-21S3

Wk 5 · Vol 0.38x

2026-10-20S3

Wk 5 · Vol 0.65x

2026-10-19S3

Wk 4 · Vol 0.79x

2026-10-16S3

Wk 4 · Vol 0.88x

2026-10-15S3

Wk 4 · Vol 0.81x

2026-10-14S3

Wk 4 · Vol 1.15x

2026-10-13S3

Wk 4 · Vol 0.94x

2026-10-12S3

Wk 3 · Vol 0.90x

2026-10-09S3

Wk 3 · Vol 1.14x

2026-10-08S3

Wk 3 · Vol 1.15x

2026-10-07S3

Wk 3 · Vol 0.76x

Moving averages & range

50 DMA

$11.27

200 DMA

$9.08

52W High

$21.38

52W Low

$1.93

5D Low

$7.52

Resistance levels (recent highs)

20d High

$9.53

60d High

$16.49

120d High

$21.38

250d High

$21.38

Next resistance

+8.3%

to 20d High

P/E (TTM)

2.8

Forward -8.6

ROE

+72.1%

Profit margin +62.9%

Dividend Yield

0.00%

P/B 2.0

Q32 Bio: quick answers

What stage is Q32 Bio in?

As of Oct 22, 2026, Q32 Bio (QTTB) is in Stage 3, the topping phase. It entered Stage 3 on Sep 22, 2026 and is in week 5. What the four stages mean

Is Q32 Bio in an uptrend?

Its uptrend has stalled. Q32 Bio is in Stage 3, the topping phase that follows an advance. It trades 3.1% below its 200-day average, which is rising.

How far is Q32 Bio from its 52-week high?

Q32 Bio closed at $8.80 on Oct 22, 2026, 58.8% below its 52-week high of $21.38. Its 52-week low is $1.93.

How has Q32 Bio performed over the past year?

As of Oct 22, 2026, Q32 Bio is up 196.3% over the past year and up 155.8% so far in 2026.

Which sector and industry is Q32 Bio in?

Q32 Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.